Targeted IKZF2 degradation represents a potential therapeutic strategy for cancer immunotherapy. Here, the authors described the discovery of PVTX-405 as a potent, highly selective, and orally efficacious IKZF2 molecular glue degrader and their preclinical data support the clinical development of PVTX-405.
- Zhixiang Chen
- Harshil Dhruv
- Shaomeng Wang
